Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.
Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.